John Jefferies, the Chief Medical Officer at Daxor Corp (NASDAQ: DXR), disclosed two stock acquisitions dated March 20, 2026, totaling 5,941 shares of Daxor common stock. Both transactions were reported as acquisitions with a reported price per share of $0.0 and a total outlay listed as $0.
The filings break down the activity into two separate grants. One line records an acquisition of 3,656 shares that vest on March 20, 2029. The other entry shows 2,285 shares that vested on March 20, 2026. After these entries, Jefferies is reported to directly own 23,557 shares of Daxor common stock.
At the time of the report, Daxor’s shares were trading at $10.34. That level represents a year-to-date decline of 30.64 percent, contrasted with a 25.52 percent increase over the trailing 12 months.
Investment research from InvestingPro is cited in the filings as indicating that Daxor’s shares may be undervalued at current market levels, with analyst price targets clustered in the $22 to $23 range. The InvestingPro material is referenced as providing Fair Value estimates and financial health metrics for additional context on valuation and balance sheet considerations.
Separately, the company reported material operational and balance sheet developments for 2025. Daxor’s operating division revenue rose by 45 percent in 2025 versus the prior year, according to the information provided. Net assets increased to $45.9 million as of December 31, 2025, up from $35.8 million a year earlier.
Daxor is also in the process of converting its regulatory reporting framework. The company intends to move from reporting under the Investment Company Act of 1940 to reporting under the Securities Exchange Act of 1934, subject to required approvals. Management expects the transition to conclude by the end of the second quarter, tying the change to the growth of its diagnostic technology business.
Finally, Daxor completed a registered direct offering, generating approximately $8.1 million in net proceeds. The offering consisted of 765,958 registered shares priced at $11.75 per share and was executed under the company’s shelf registration statement, which the filing notes was declared effective by the SEC in January 2026.
The filings and corporate disclosures provide a snapshot of insider holdings, analyst valuation views and recent corporate finance activity as shareholders and market participants assess the company’s financial positioning and reporting transition.